BD granted FDA Emergency Use Authorization for COVID-19, Flu, RSV combo test
BD,a leading global medical technology company, had announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) to help combat illness in the current and future respiratory virus seasons.